Treatment Options for HER2+ MBC With Brain Metastasis
August 3rd 2021Options available to treat patients with HER2-positive metastatic breast cancer and brain metastasis, and factors that impact choice of therapy based on CNS data demonstrated in several clinical trials of HER2-targeted agents.
Read More
Updates in HER2+ MBC: The NALA and SOPHIA Trials
July 13th 2021Dr Lee Schwartzberg, MD, FASCO, highlights the appropriateness for treating HER2-positive metastatic breast cancer with either neratinib plus capecitabine or margetuximab plus chemotherapy based on evidence revealed by the NALA and SOPHIA clinical trials.
Read More